Skip to main content

Alnylam Completes Enrollment in Phase II Study of ATTR Drug

Premium

Alnylam Pharmaceuticals this week announced that it has completed enrollment in a phase II trial of its lipid nanoparticle-formulated TTR-mediated amyloidosis treatment ALN-TTR02.

The phase II open-label trial is evaluating two doses of ALN-TTR02, ranging from 0.01 mg/kg to 0.30 mg/kg, in 29 patients with ATTR polyneuropathy. Patients are treated either once every four weeks or once every three weeks.

This summer, the company reported positive interim data from the trial showing that its drug was able to knock down levels of the protein that causes the disease by as much as 93 percent (GSN 7/3/2013).

Alnylam said that it remains on track to begin a phase III trial of ALN-TTR02 in ATTR patients with a manifestation of the condition called familial amyloidotic polyneuropathy by the end of this year.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.